Remove Avalon Remove Blogging Remove Technology
article thumbnail

Cheezburger Deal Spawned Out Of LA's TwiistUp

socalTECH

and FAIL Blog web sites, apparently was spawned out of an introduction at last year's Twiistup technology conference, according to investor the Foundry Group. Along with Foundry, both Madrona Ventures and San Diego's Avalon Ventures were investors in the round. READ MORE>>.

Twiistup 145
article thumbnail

Avalon Leads $18M in Early Funding for Cancer Immunotherapy Startup

Xconomy

San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups). Lilly Asia Ventures, Osage University Partners, and Vivo Capital joined in the deal, according to a statement from Avalon. Bregua Corp.,

Avalon 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Avelas Bio Raises $20M to Push Cancer-Illuminating Biologic Agent

Xconomy

and San Diego’s Avalon Ventures. Stengone said the new funding also will help the company evaluate the use of AVB-620 in other types of cancer surgery, to advance new cancer drugs that rely on Avelas’ proprietary technology, and to expand the company’s current roster of “seven employees and an army of consultants.”.

Avalon 40
article thumbnail

Synthorx Gets $131M In Upsized IPO For Synthetic Biology Drugs

Xconomy

Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.

article thumbnail

Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs

Xconomy

After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs , San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.

article thumbnail

Synthorx Raises $10M to Expand Use of Synthetic DNA in Biologics

Xconomy

Existing investors Avalon Ventures and Correlation Ventures joined in the round. The company’s technology is based on research led by Floyd Romesberg, a biological chemist at The Scripps Research Institute. The San Diego firms have invested $6 million since 2014, when Synthorx was founded , CEO Court Turner said yesterday.

article thumbnail

Smarr, Others Talk Healthtech, AI at Xconomy’s Impact of Innovation

Xconomy

This is the direction we’re headed, according to Larry Smarr, founding director of the California Institute of Telecommunications & Information Technology at UC San Diego.